Smritisikha Bora

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Linagliptin, a dipeptidyl peptidase 4 (DPP 4) inhibitor with a long terminal half life, significantly inhibits the DPP 4 enzyme at a steady state up to 48 h after the last dose. The present case series examined the hypothesis that linagliptin retains its efficacy during alternate day dosing in type 2 diabetes patients when switched over from once daily (OD)(More)
  • 1